219 related articles for article (PubMed ID: 30619094)
1. Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration.
Ferrari SM; La Motta C; Elia G; Ragusa F; Ruffilli I; Quattrini L; Paparo SR; Piaggi S; Patrizio A; Ulisse S; Baldini E; Materazzi G; Fallahi P; Antonelli A
Front Endocrinol (Lausanne); 2018; 9():764. PubMed ID: 30619094
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration.
Antonelli A; Ferrari SM; Fallahi P; Berti P; Materazzi G; Marchetti I; Ugolini C; Basolo F; Miccoli P; Ferrannini E
Eur J Endocrinol; 2008 Sep; 159(3):283-91. PubMed ID: 18583391
[TBL] [Abstract][Full Text] [Related]
3. Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture.
Ferrari SM; Elia G; Ragusa F; Paparo SR; Mazzi V; Patrizio A; Piaggi S; Baldini E; Centanni M; La Motta C; Antonelli A; Fallahi P
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768721
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
5. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
6. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests.
Antonelli A; Ferrari SM; Fallahi P; Berti P; Materazzi G; Barani L; Marchetti I; Ferrannini E; Miccoli P
Clin Endocrinol (Oxf); 2008 Jul; 69(1):148-52. PubMed ID: 18194485
[TBL] [Abstract][Full Text] [Related]
7. Novel treatments for anaplastic thyroid carcinoma.
Ferrari SM; Elia G; Ragusa F; Ruffilli I; La Motta C; Paparo SR; Patrizio A; Vita R; Benvenga S; Materazzi G; Fallahi P; Antonelli A
Gland Surg; 2020 Jan; 9(Suppl 1):S28-S42. PubMed ID: 32055496
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer.
Su X; Liu J; Zhang H; Gu Q; Zhou X; Ji M; Yao D
Onco Targets Ther; 2020; 13():11183-11192. PubMed ID: 33173310
[TBL] [Abstract][Full Text] [Related]
9. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer.
Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
Cancer Chemother Pharmacol; 2018 Oct; 82(4):649-654. PubMed ID: 30051190
[TBL] [Abstract][Full Text] [Related]
10. Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report.
Yamazaki H; Masudo K; Kanada S; Inayama Y; Hayashi H; Fujii Y; Rino Y
Surg Case Rep; 2023 Mar; 9(1):38. PubMed ID: 36920674
[TBL] [Abstract][Full Text] [Related]
11. Novel treatment options for anaplastic thyroid cancer.
Fallahi P; Ruffilli I; Elia G; Ragusa F; Ulisse S; Baldini E; Miccoli M; Materazzi G; Antonelli A; Ferrari SM
Expert Rev Endocrinol Metab; 2017 Jul; 12(4):279-288. PubMed ID: 30058884
[TBL] [Abstract][Full Text] [Related]
12. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
14. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
Hamamoto T; Kono T; Taruya T; Ishino T; Ueda T; Takeno S
Auris Nasus Larynx; 2022 Jun; 49(3):515-519. PubMed ID: 33109426
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
16. Nasogastric administration of lenvatinib solution in a mechanically ventilated patient with rapidly growing anaplastic thyroid cancer.
Kawano F; Yonekawa T; Yamaguchi H; Shibata N; Tashiro K; Ikenoue M; Munakata S; Higuchi K; Tanaka H; Sato Y; Hosokawa A; Takeno S; Nakamura K; Nanashima A
Endocrinol Diabetes Metab Case Rep; 2020 Aug; 2020():. PubMed ID: 32755964
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.
Koyama S; Miyake N; Fujiwara K; Morisaki T; Fukuhara T; Kitano H; Takeuchi H
Eur Thyroid J; 2018 Jun; 7(3):139-144. PubMed ID: 30023346
[TBL] [Abstract][Full Text] [Related]
20. Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.
Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
Eur J Clin Pharmacol; 2020 May; 76(5):703-709. PubMed ID: 32034430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
